Hyloris Pharmaceuticals SA (HYL.BR)
EUR 6.7
(-0.31%)
EUR 6.7
(-0.31%)
| Year | Eps | Eps Growth |
|---|---|---|
| 2023 | -0.55 EUR | -37.5% |
| 2022 | -0.40 EUR | 11.11% |
| 2021 | -0.45 EUR | -60.71% |
| 2020 | -0.28 EUR | 75.65% |
| 2019 | -1.15 EUR | -360.0% |
| 2018 | -0.25 EUR | -56.25% |
| 2017 | -0.16 EUR | 0.0% |
| Year | Eps | Eps Growth |
|---|---|---|
| 2023 Q2 | -0.12 EUR | 0.0% |
| 2023 Q3 | -0.16 EUR | -33.33% |
| 2023 Q1 | - EUR | 100.0% |
| 2023 FY | - EUR | -37.5% |
| 2023 Q4 | -0.16 EUR | 0.0% |
| 2022 Q2 | -0.19 EUR | -100.0% |
| 2022 FY | - EUR | 11.11% |
| 2022 Q4 | -0.12 EUR | 0.0% |
| 2022 Q3 | -0.12 EUR | 36.84% |
| 2022 Q1 | -0.10 EUR | 26.92% |
| 2021 FY | - EUR | -60.71% |
| 2021 Q4 | -0.13 EUR | -100.0% |
| 2021 Q3 | -0.06 EUR | 79.69% |
| 2021 Q2 | -0.32 EUR | -100.0% |
| 2021 Q1 | -0.16 EUR | -139.16% |
| 2020 Q2 | -0.10 EUR | -49.03% |
| 2020 FY | - EUR | 75.65% |
| 2020 Q4 | -0.07 EUR | 0.0% |
| 2020 Q1 | -0.07 EUR | 66.45% |
| 2020 Q3 | -0.07 EUR | 33.1% |
| 2019 Q2 | -0.02 EUR | 16.04% |
| 2019 Q3 | -0.20 EUR | -713.01% |
| 2019 Q1 | -0.03 EUR | 0.0% |
| 2019 FY | - EUR | -360.0% |
| 2019 Q4 | -0.20 EUR | 0.0% |
| 2018 FY | - EUR | -56.25% |
| 2017 FY | - EUR | 0.0% |
| Name | Eps | Eps Difference |
|---|---|---|
| Nicox S.A. | -0.42 EUR | -30.952% |
| European Medical Solutions | -0.00 EUR | -109900.0% |
| FERMENTALG | -0.32 EUR | -71.875% |
| argenx SE | -4.67 EUR | 88.223% |
| BioSenic S.A. | -0.21 EUR | -161.905% |
| Celyad Oncology SA | -0.33 EUR | -66.667% |
| Onward Medical N.V. | -1.20 EUR | 54.167% |
| Oxurion NV | -0.01 EUR | -4682.609% |
| PHAXIAM Therapeutics S.A. | -5.00 EUR | 89.0% |
| Financière de Tubize SA | 1.98 EUR | 127.778% |
| UCB SA | 1.81 EUR | 130.387% |